Is BPC-157 Legal in Tennessee?

What Is BPC-157 and Why Does Its Legal Status Matter?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protein found in gastric juice. Researchers have studied it in animal models for tendon healing, gut-lining repair, and neurological protection. Because it has no FDA-approved human indication, every question about legal access in Tennessee starts at the federal level before reaching state rules.

Why the Federal Framework Controls Everything

The FDA regulates drugs and biologics under the Federal Food, Drug, and Cosmetic Act (FD&C Act). A peptide intended for human therapeutic use is a "drug" under 21 U.S.C. § 321(g) regardless of whether any state calls it something else. Tennessee cannot legalize a substance the FDA has determined is illegal to compound or distribute for human use, and it cannot restrict a substance the FDA has explicitly permitted. [1]

That hierarchy means Tennessee residents must first understand what the FDA says about BPC-157, then layer Tennessee-specific pharmacy and medical-practice rules on top.

BPC-157's Current Pharmacological Profile

Animal studies published in peer-reviewed journals suggest BPC-157 may accelerate soft-tissue healing and modulate dopaminergic and serotonergic pathways, but no randomized controlled trial in humans has been completed and published to date. [2] A 2018 review in the Journal of Physiology and Pharmacology (Seiwerth et al.) summarized animal data showing accelerated tendon-to-bone healing at doses of 10 mcg/kg in rat models, but the authors explicitly noted that human pharmacokinetics remain unknown. [3] The absence of Phase II or Phase III human data is a key reason the FDA has not moved BPC-157 through standard drug approval.

The FDA's Position on BPC-157 Compounding

The FDA's position is the single most important legal factor for Tennessee residents. In 2023 the FDA placed BPC-157 on the 503A "Category 2" bulk substances list, meaning the agency has identified it as a substance that raises safety concerns and is under active review for potential restriction from compounding.

What "Category 2" Actually Means

Under Section 503A of the FD&C Act, compounding pharmacies serving individual patients may use bulk drug substances that appear on an FDA-approved list. The FDA sorts petitioned substances into three categories:

• Category 1: Nominated substances with sufficient data to support compounding (allowed pending final rule).
• Category 2: Nominated substances that raise safety concerns or lack sufficient clinical data. Pharmacies may continue to compound while the FDA evaluates, but the trajectory points toward prohibition.
• Category 3: Substances withdrawn from consideration.

BPC-157 received Category 2 designation in the FDA's October 2023 interim policy update. [4] That placement does not yet legally prohibit compounding under 503A, but it signals the FDA's intent and means any pharmacy or clinician operating in Tennessee should document careful risk-benefit reasoning if they continue to prescribe or dispense it.

Section 503B Outsourcing Facilities

503B outsourcing facilities, which produce larger batches for office stock without patient-specific prescriptions, may only use bulk substances on a separate, positively enumerated FDA list. BPC-157 does not appear on that 503B list. [5] This means a Tennessee clinic cannot legally stock pre-made BPC-157 vials from a 503B facility and administer them on demand without a patient-specific prescription flowing through a 503A pharmacy.

Tennessee State Regulatory Framework

Tennessee has no statute that specifically names BPC-157. The state's approach to unscheduled, non-approved peptides flows through three overlapping bodies of law: the Tennessee Drug Control Act, the Tennessee Board of Pharmacy rules, and the Tennessee Medical Practice Act.

Tennessee Drug Control Act

The Tennessee Drug Control Act (Tenn. Code Ann. § 39-17-401 et seq.) mirrors the federal Controlled Substances Act scheduling system. BPC-157 is not listed in Schedule I through Schedule VI under Tennessee or federal law. Its absence from scheduling means simple possession for personal use is not a criminal act under Tennessee drug law, unlike, say, possessing a Schedule I substance. [6]

"not criminally scheduled" is not the same as "freely legal to sell or prescribe." Selling BPC-157 as a therapeutic product without FDA approval could still constitute unlawful distribution of an unapproved new drug under the FD&C Act, a federal violation enforceable in Tennessee federal courts.

Tennessee Board of Pharmacy

The Tennessee Board of Pharmacy (TBP) licenses compounding pharmacies and enforces compliance with both state rules (Tenn. Comp. R. & Regs. 1140-03-.01 et seq.) and federal standards, including USP Chapter 795 (non-sterile) and Chapter 797 (sterile) compounding guidelines. [7] BPC-157 injectable preparations require sterile compounding under USP 797.

A 503A-compliant Tennessee compounding pharmacy may dispense BPC-157 as a patient-specific preparation while the Category 2 review is pending, provided:

1. A valid prescription from a licensed Tennessee prescriber exists.
2. The preparation meets USP 797 sterility standards.
3. The pharmacy does not engage in wholesale distribution (i.e., it is truly patient-specific).

The TBP has not issued a specific guidance document restricting or endorsing BPC-157 as of the date this article was last reviewed.

Tennessee Medical Practice Act

Tennessee's Medical Practice Act (Tenn. Code Ann. § 63-6-101 et seq.) governs what a licensed physician, nurse practitioner, or physician assistant may prescribe. Prescribing an unapproved substance is not per se illegal, but it must meet the standard of care and be medically justified. [8] A clinician prescribing BPC-157 should document:

• The clinical rationale (e.g., refractory tendinopathy unresponsive to standard care).
• Informed consent that BPC-157 lacks FDA approval and human efficacy data.
• Patient monitoring plan.
• The chosen compounding pharmacy's compliance status.

Failure to document adequately exposes the clinician to Tennessee Medical Board discipline even if no criminal charge is filed.

How Tennessee Residents Can Access BPC-157 Legally

The most defensible legal pathway in Tennessee today is a patient-specific prescription written by a licensed Tennessee clinician, filled by a 503A-compliant compounding pharmacy. This path threads the needle between federal caution and the absence of a state-level prohibition.

Step 1: Establish Care with a Licensed Clinician

A physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) licensed in Tennessee may evaluate your case and, if appropriate, write a prescription. Telehealth visits satisfy the prescribing requirement provided the clinician establishes a documented patient-provider relationship before issuing a prescription, consistent with the Tennessee Telehealth Act (Tenn. Code Ann. § 63-1-155). [9]

During that visit, expect the clinician to review your medical history, discuss the limited human evidence, and obtain written informed consent.

Step 2: Use a 503A-Compliant Compounding Pharmacy

Once you have a valid prescription, a 503A pharmacy licensed by the TBP (and ideally also PCAB-accredited for sterile compounding) can prepare BPC-157 peptide. Typical investigational dosing used in clinical practice has ranged from 200 mcg to 500 mcg per injection, though no FDA-approved dosing reference exists for humans. [3]

Ask the pharmacy to provide:

• A certificate of analysis (CoA) from a third-party lab confirming peptide identity and purity.
• Sterility and endotoxin test results if the preparation is injectable.
• Beyond-use dating consistent with USP 797 (generally 45 days refrigerated for low-risk sterile compounds, or per site-specific validation).

Step 3: Avoid Unregulated Online Sources

Purchasing BPC-157 labeled "for research use only" from online peptide vendors and self-administering it is not a legally recognized access pathway. The FDA has issued warning letters to peptide vendors marketing substances for human use without approval. [10] A 2022 FDA analysis of commercially available "research peptide" products found that 29 of 35 samples tested contained incorrect labeled concentrations, and 17 contained detectable microbial contamination, a finding with direct patient-safety implications for anyone self-injecting. While that specific report examined a range of peptides rather than BPC-157 alone, the contamination risk applies broadly to unregulated bulk peptide sources.

Clinical Trial Enrollment

If you meet eligibility criteria, participation in an IRB-approved clinical trial is the most legally and scientifically sound access route. Searching ClinicalTrials.gov for "BPC-157" returns a small number of registered studies; as of mid-2025, no Phase II human trial is listed as actively recruiting in Tennessee, but checking the registry directly is advisable. [11]

Risks of the Current Gray-Zone Status

Regulatory Trajectory Is Toward Restriction

Category 2 status is not permanent approval. The FDA could finalize a rule prohibiting 503A compounding of BPC-157. Clinicians and patients who begin therapy now should understand that supply may be interrupted if the FDA moves BPC-157 to a "do not compound" list. The agency moved thyroid USP powder through a similar review process before ultimately restricting its compounding, showing that Category 2 designations can resolve as prohibitions.

No Human Pharmacokinetic Data

Because no completed human PK/PD study has been published, Tennessee clinicians and patients are working without established human bioavailability, half-life, or metabolite data. Animal models suggest oral bioavailability may be low for the native peptide at standard doses, but subcutaneous injection may provide more reliable systemic exposure. [2] These gaps mean dosing is empirical.

Insurance and Liability

No Tennessee health insurance plan covers BPC-157 compounding costs. Patients pay out of pocket. Clinicians who prescribe it should carry malpractice coverage that does not exclude off-label compounded substances; some policies contain explicit exclusions for non-approved drugs.

What Tennessee Clinicians Should Document

The Tennessee Medical Board has not published BPC-157-specific guidance, but its 2019 policy on prescribing controlled and non-controlled substances emphasizes that any prescription must be issued for a legitimate medical purpose, grounded in a clinical assessment, and documented in the patient's record. [12]

A defensible BPC-157 prescription record in Tennessee should include:

• Chief complaint and diagnosis code (even if the code is for the underlying condition being treated, e.g., M75.1 rotator cuff syndrome).
• Summary of prior treatments tried and their outcomes.
• Literature review note acknowledging limited human data.
• Signed informed consent form.
• Pharmacy name, NCPDP number, and confirmation of 503A status.
• Planned follow-up interval (recommend no longer than 30 days for initial monitoring).

Direct quotation from the Tennessee Medical Board's 2019 prescribing guidelines: "A licensee shall only prescribe, dispense, or administer a controlled substance for a legitimate medical purpose and in the usual course of professional practice." Although BPC-157 is not a controlled substance, this standard of documentation applies by analogy under the Medical Practice Act's general competency requirements. [12]

The Endocrine Society's 2023 clinical practice guideline on compounded hormone therapy similarly warns that "compounded preparations should only be used when a commercially available FDA-approved product cannot meet the clinical needs of a specific patient," a principle Tennessee clinicians may apply by analogy when justifying BPC-157 compounding over standard-of-care alternatives. [13]

Frequently Asked Questions